Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease. It is a slightly modified recombinant version of the human interleukin 1 receptor antagonist protein.<\/p>\n
Kineret is not widely marketed in India. It is usually accessed through a special import process under the Named Patient Program (NPP). For assistance and guidance, you can contact us by providing complete details. Like 1. How to get access in India. 2. Imported Medicine Pricing Estimates in India (Subject to Doctor\u2019s Prescription and Regulations) 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n Need urgent access to Kineret? We\u2019re here to help.<\/strong><\/p>\n Call Now | Enquire Today | WhatsApp Support Available India Pharma Network (IPN):<\/strong> Headquartered in New Delhi, with branch offices in Mumbai, Delhi, Gurugram, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedabad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tirupur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.<\/strong>\u00a0IPN facilitates access to medicines through legally compliant import pathways. Such access is arranged on a Named Patient basis and is intended strictly for personal use, in accordance with applicable regulations and subject to a valid medical prescription and necessary approvals.<\/p>\n NEWS\/UPDATES<\/p>\n India Pharma Network acts solely as a facilitator for Kineret (anakinra) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:<\/p>\n The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" Kineret (anakinra) is indicated for treating moderately to severely active Rheumatoid Arthritis (RA) in adults failing other DMARDs, and for rare autoinflammatory conditions like Cryopyrin-Associated Periodic Syndromes (CAPS), including NOMID, and Deficiency of Interleukin-1 Receptor Antagonist (DIRA), plus Still’s Disease (SJIA\/AOSD) in specific age groups, working by blocking inflammation-causing interleukin-1. It’s an immunosuppressant that blocks immune chemical messengers.<\/p>\nGet Help for Kineret Import<\/h4>\n
\n
\n<\/strong>Mobile\/WhatsApp:\u00a0Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774.\u00a0<\/strong><\/span>
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/span><\/p>\n\n
Compliance & Disclaimer<\/h5>\n
\n
Kineret (anakinra) \u2013 Rheumatoid Arthritis (RA) Therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n Kineret<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n anakinra<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Injection: 100 mg\/0.67 mL solution in a single-use prefilled syringe for
\nsubcutaneous injection. Graduated syringe allows for doses between 20 mg and 100 mg.<\/td>\n<\/tr>\n\n Manufacturer:<\/strong><\/td>\n Swedish Orphan Biovitrum AB (publ)<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n